Earnings per share for the last twelve months: Calidi Biotherapeutics Inc. (CLDI)

Calidi Biotherapeutics (CLDI) creates value through patents for the delivery of stem cells to neoplasms, although the business is currently depleting reserves on costly research without current sales. The company's rolling annual per-share profit reflects capital dynamics, where the current value is -54.04. The development of virotherapy relies on the acquisition of bioengineering rights and synergy with external laboratories.

The market values Calidi Biotherapeutics (CLDI) based on the potential of the StemVac platform and the security of its R&D. Net income per share over 12 months measures the total income distributed across the entire volume of issuance, neutralizing short-term quarterly fluctuations. By analyzing the rolling annual earnings per share, an investor can see the actual efficiency of intellectual property capitalization. For a biotech company, this serves as an indicator of the transition from development costs to patent monetization. The dynamics of this metric confirm the financial stability of the business.